BCIQ Profiles

Company Profile ReportTarget Profile Report

J&J ends deal for Macrogenics' duvortuxizumab

MacroGenics Inc. (NASDAQ:MGNX) said the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) terminated its license to duvortuxizumab (MGD011), a bispecific

Read the full 228 word article

How to gain access

Continue reading with a
two-week free trial.